Skip to main content
SpringerLink
Log in

Switching to Stribild: good strategy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. gastrointestinal

Reference

  • Gathe J, et al. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. The Patient - Patient-Centered Outcomes Research : 19 Aug 2015. Available from: URL: http://dx.doi.org/10.1007/s40271-015-0137-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Switching to Stribild: good strategy. PharmacoEcon Outcomes News 736, 22 (2015). https://doi.org/10.1007/s40274-015-2432-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2432-z

Search

Navigation